Aridis Pharmaceuticals to Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19

Rhea-AI Summary

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) announced participation in the Cantor Fitzgerald Virtual Symposium titled "Winning Ways to Treat Infections and COVID-19," scheduled for June 30, 2020, at 11:00 AM ET. CEO Vu Truong will represent the company, which focuses on developing novel anti-infective therapies for severe bacterial infections. Aridis utilizes its proprietary technology platforms to create monoclonal antibodies (mAbs) targeting life-threatening infections and is advancing several clinical programs.

Positive

• Participation in a notable virtual symposium can enhance the company's visibility.
• Development of multiple clinical-stage mAbs targeting critical infections indicates a robust pipeline.

Negative

• None.

SAN JOSE, Calif., June 26, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, today announced that Vu Truong, Ph.D., Chief Executive Officer, will participate in Cantor Fitzgerald's Virtual Symposium: "Winning Ways to Treat Infections and COVID-19" being held on Tuesday, June 30, 2020.

Symposium Details:
Panel: Winning Ways to Treat Infections and COVID-19
Date: Tuesday, June 30, 2020 
Time: 11:00AM ET

To register for the virtual symposium, please click here: Virtual Symposium Registration.

About Aridis Pharmaceuticals, Inc.
Aridis Pharmaceuticals, Inc. discovers and develops anti-infectives to be used as add-on treatments to standard-of-care antibiotics. The Company is utilizing its proprietary /PEX^™ and MabIgX® technology platforms to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome an infection, and to rapidly manufacture mAbs for therapeutic treatment of critical infections. These mAbs are already of human origin and functionally optimized for high potency by the donor's immune system; hence, they do not require genetic engineering or further optimization to achieve full functionality.

The Company has generated multiple clinical stage mAbs targeting bacteria that cause life-threatening infections such as ventilator associated pneumonia (VAP) and preclinical stage antiviral mAbs. The use of mAbs as anti-infective treatments represents an innovative therapeutic approach that harnesses the human immune system to fight infections and is designed to overcome the deficiencies associated with the current standard of care which is broad spectrum antibiotics. Such deficiencies include, but are not limited to, increasing drug resistance, short duration of efficacy, disruption of the normal flora of the human microbiome and lack of differentiation among current treatments. The mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to treat lung infections in cystic fibrosis patients. The Company's pipeline is highlighted below:

Aridis' Pipeline

AR-301 (VAP). AR-301 is a fully human immunoglobulin 1, or IgG1, mAb currently in Phase 3 clinical development targeting gram-positive S. aureus alpha-toxin in VAP patients.

AR-101 (HAP). AR-101 is a fully human immunoglobulin M, or IgM, mAb in Phase 2 clinical development targeting P. aeruginosa liposaccharides serotype O11, which accounts for approximately 22% of all P. aeruginosa hospital acquired pneumonia cases worldwide.

AR-501 (cystic fibrosis). AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in cystic fibrosis patients.  This program is currently in a Phase 1/2a clinical study in healthy volunteers and CF patients.

AR-401 (blood stream infections). AR-401 is a fully human mAb preclinical program aimed at treating infections caused by gram-negative Acinetobacter baumannii.

AR-701 (COVID-19). AR-701 is a fully human mAb cocktail discovered from convalescent COVID-19 patients that are directed at multiple envelope proteins on SARS-CoV-2. 

AR-201 (RSV infection). AR-201 is a fully human IgG1 mAb out-licensed preclinical program aimed at neutralizing diverse clinical isolates of respiratory syncytial virus (RSV).

For additional information on Aridis Pharmaceuticals, please visit https://aridispharma.com/.

Contact:

Investor Relations
Jason Wong
Blueprint Life Science Group
jwong@bplifescience.com
(415) 375-3340 Ext. 4

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/aridis-pharmaceuticals-to-participate-in-cantor-fitzgerald-virtual-symposium-winning-ways-to-treat-infections-and-covid-19-301084143.html

SOURCE Aridis Pharmaceuticals, Inc.

FAQ

What is the date of Aridis Pharmaceuticals' participation in the virtual symposium?

Aridis Pharmaceuticals will participate in the virtual symposium on June 30, 2020.

Who is the CEO of Aridis Pharmaceuticals?

The CEO of Aridis Pharmaceuticals is Vu Truong, Ph.D.

What is the focus of Aridis Pharmaceuticals?

Aridis Pharmaceuticals focuses on developing novel anti-infective therapies for life-threatening bacterial infections.

What technologies does Aridis Pharmaceuticals utilize?

Aridis Pharmaceuticals utilizes proprietary technology platforms such as PEX and MabIgX to develop monoclonal antibodies.

What are some of the clinical programs in Aridis' pipeline?

Aridis' pipeline includes AR-301 for VAP, AR-101 for HAP, and AR-501 for cystic fibrosis.